NASDAQ: IKT - Inhibikase Therapeutics, Inc.

六个月盈利: +152.07%
股息率: 0.00%
部门: Healthcare

促销时间表 Inhibikase Therapeutics, Inc.

先进的时间表 简单图表
Financial Markets by TradingView

关于公司 Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc.

更多详情
has research and development collaborations with Johns Hopkins University, Arizona State University, University of Bordeaux, and Michigan State University, as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
添加到比较列表
添加到观察列表
添加到投资组合
添加价格通知

IPO date 2020-12-23
ISIN US45719W1062
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.inhibikase.com
Цена ао 2.29
每日价格变化: -0.3268% (3.06)
每周价格变化: -4.69% (3.2)
每月价格变化: +11.72% (2.73)
3个月内价格变化: +160.68% (1.17)
六个月内的价格变化: +152.07% (1.21)
每年价格变化: +140.16% (1.27)
3年内价格变化: +87.12% (1.63)
5年内价格变化: 0% (3.05)
10年价格变化: 0% (3.05)
年初以来价格变化: +51.74% (2.01)
所有参数

低估

姓名 意义 年级
P/S 25.18 1
P/BV 0.5975 10
P/E 0 0
EV/EBITDA 0.0996 10
全部的: 5.13

效率

姓名 意义 年级
ROA, % -131.17 0
ROE, % -173.34 0
全部的: 0

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0 0
全部的: 0

责任

姓名 意义 年级
Debt/EBITDA -0.0312 10
全部的: 10

成长冲动

姓名 意义 年级
盈利能力 Revenue, % -76.32 0
盈利能力 Ebitda, % 249.34 10
盈利能力 EPS, % 3.72 1
全部的: 6.2
更多详情

机构 体积 分享, %
Armistice Capital, LLC 186046 3.01
Vanguard Group Inc 87447 1.42
Blair (William) & Company, L.L.C. 59375 0.96
Geode Capital Management, LLC 28692 0.46
Redmond Asset Management, LLC 20977 0.34
Edgewood Management Llc 16666 0.27
Renaissance Technologies, LLC 16122 0.26
State Street Corporation 10084 0.16
Tower Research Capital LLC (TRC) 2200 0.04
Morgan Stanley 1667 0.03



导师 职称 支付 出生年份
Dr. Milton H. Werner Ph.D. CEO, President & Director 697.96k 1964 (61 年)
Dr. Surendra Singh Head of Chemistry, Manufacturing & Controls N/A
Dr. Charles Warren Olanow B.Sc., F.R.C.P.C., M.D. CEO of Clintrex Research Corporation & Member of Scientific Advisory Board N/A
Dan Williams Controller N/A
Mr. Garth Lees-Rolfe CPA Chief Financial Officer N/A 1985 (40 年)

地址: United States, Atlanta. GA, 3350 Riverwood Parkway SE - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://www.inhibikase.com